Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.08
BSX's Cash to Debt is ranked lower than
56% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. BSX: 0.08 )
BSX' s 10-Year Cash to Debt Range
Min: 0.03   Max: 4.11
Current: 0.08

0.03
4.11
Equity to Asset 0.40
BSX's Equity to Asset is ranked higher than
52% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. BSX: 0.40 )
BSX' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.79
Current: 0.4

0.18
0.79
Interest Coverage 0.37
BSX's Interest Coverage is ranked lower than
62% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 155.63 vs. BSX: 0.37 )
BSX' s 10-Year Interest Coverage Range
Min: 0.37   Max: 65
Current: 0.37

0.37
65
F-Score: 8
Z-Score: 0.94
M-Score: -2.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 4.34
BSX's Operating margin (%) is ranked higher than
70% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 6.58 vs. BSX: 4.34 )
BSX' s 10-Year Operating margin (%) Range
Min: -53.36   Max: 28.95
Current: 4.34

-53.36
28.95
Net-margin (%) 3.93
BSX's Net-margin (%) is ranked higher than
71% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 5.11 vs. BSX: 3.93 )
BSX' s 10-Year Net-margin (%) Range
Min: -56.12   Max: 18.88
Current: 3.93

-56.12
18.88
ROE (%) 4.38
BSX's ROE (%) is ranked higher than
69% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 5.84 vs. BSX: 4.38 )
BSX' s 10-Year ROE (%) Range
Min: -44.65   Max: 30.84
Current: 4.38

-44.65
30.84
ROA (%) 1.73
BSX's ROA (%) is ranked higher than
68% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 3.49 vs. BSX: 1.73 )
BSX' s 10-Year ROA (%) Range
Min: -21.16   Max: 15.31
Current: 1.73

-21.16
15.31
ROC (Joel Greenblatt) (%) 12.30
BSX's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 12.36 vs. BSX: 12.30 )
BSX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -145.85   Max: 139.6
Current: 12.3

-145.85
139.6
Revenue Growth (%) 1.20
BSX's Revenue Growth (%) is ranked higher than
66% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. BSX: 1.20 )
BSX' s 10-Year Revenue Growth (%) Range
Min: -10.5   Max: 28.9
Current: 1.2

-10.5
28.9
EBITDA Growth (%) 80.70
BSX's EBITDA Growth (%) is ranked higher than
98% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -1.20 vs. BSX: 80.70 )
BSX' s 10-Year EBITDA Growth (%) Range
Min: -72   Max: 283.2
Current: 80.7

-72
283.2
EPS Growth (%) -49.50
BSX's EPS Growth (%) is ranked higher than
51% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. BSX: -49.50 )
BSX' s 10-Year EPS Growth (%) Range
Min: -49.5   Max: 124.6
Current: -49.5

-49.5
124.6
» BSX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

BSX Guru Trades in Q3 2013

Paul Tudor Jones 13,100 sh (New)
Steven Cohen 293,313 sh (+312.96%)
Diamond Hill Capital 20,669,649 sh (+1%)
Michael Price 1,700,000 sh (unchged)
Charles Brandes Sold Out
Pioneer Investments Sold Out
Stanley Druckenmiller Sold Out
PRIMECAP Management 48,662,519 sh (-0.77%)
Mario Gabelli 2,234,905 sh (-11.99%)
Vanguard Health Care Fund 38,240,700 sh (-15.74%)
Leon Cooperman 13,467,416 sh (-18.19%)
Dodge & Cox 59,157,107 sh (-27.68%)
Jim Simons 4,803,505 sh (-53.54%)
Joel Greenblatt 18,744 sh (-69.22%)
» More
Q4 2013

BSX Guru Trades in Q4 2013

Ray Dalio 123,584 sh (New)
Jeremy Grantham 78,020 sh (New)
Steven Cohen 2,984,052 sh (+917.36%)
Michael Price 2,000,000 sh (+17.65%)
Diamond Hill Capital 21,034,396 sh (+1.76%)
Steven Cohen 1,657,400 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 48,405,219 sh (-0.53%)
Mario Gabelli 2,201,305 sh (-1.5%)
Vanguard Health Care Fund 36,787,000 sh (-3.8%)
Jim Simons 4,358,620 sh (-9.26%)
Dodge & Cox 45,938,468 sh (-22.34%)
Leon Cooperman 8,533,099 sh (-36.64%)
» More
Q1 2014

BSX Guru Trades in Q1 2014

Paul Tudor Jones 17,944 sh (New)
PRIMECAP Management 49,351,819 sh (+1.96%)
Diamond Hill Capital 21,043,292 sh (+0.04%)
Michael Price 2,000,000 sh (unchged)
Leon Cooperman 8,533,099 sh (unchged)
Vanguard Health Care Fund 36,787,000 sh (unchged)
Jeremy Grantham Sold Out
Dodge & Cox 45,224,168 sh (-1.55%)
Mario Gabelli 2,099,005 sh (-4.65%)
Steven Cohen 2,042,403 sh (-31.56%)
Jim Simons 1,494,405 sh (-65.71%)
Ray Dalio 36,884 sh (-70.15%)
» More
Q2 2014

BSX Guru Trades in Q2 2014

Paul Tudor Jones 27,040 sh (+50.69%)
Vanguard Health Care Fund 42,743,200 sh (+16.19%)
Diamond Hill Capital 21,615,122 sh (+2.72%)
Michael Price 2,000,000 sh (unchged)
Ray Dalio Sold Out
Dodge & Cox 44,872,818 sh (-0.78%)
PRIMECAP Management 48,452,019 sh (-1.82%)
Mario Gabelli 1,785,836 sh (-14.92%)
Leon Cooperman 6,549,479 sh (-23.25%)
Jim Simons 540,205 sh (-63.85%)
» More
» Details

Insider Trades

Latest Guru Trades with BSX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Leon Cooperman 2014-06-30 Reduce -23.25%0.35%$12.58 - $13.77 $ 12.990%6549479
Vanguard Health Care Fund 2014-06-30 Add 16.19%0.2%$12.58 - $13.77 $ 12.990%42743200
Ray Dalio 2014-06-30 Sold Out $12.58 - $13.77 $ 12.990%0
Ray Dalio 2014-03-31 Reduce -70.15%0.01%$11.91 - $13.98 $ 12.99-1%36884
Leon Cooperman 2013-12-31 Reduce -36.64%0.88%$11.18 - $12.38 $ 12.9910%8533099
Michael Price 2013-12-31 Add 17.65%0.47%$11.18 - $12.38 $ 12.9910%2000000
Dodge & Cox 2013-12-31 Reduce -22.34%0.18%$11.18 - $12.38 $ 12.9910%45938468
Ray Dalio 2013-12-31 New Buy0.01%$11.18 - $12.38 $ 12.9910%123584
Joel Greenblatt 2013-12-31 Sold Out 0.01%$11.18 - $12.38 $ 12.9910%0
Leon Cooperman 2013-09-30 Reduce -18.19%0.42%$9.15 - $11.99 $ 12.9920%13467416
Dodge & Cox 2013-09-30 Reduce -27.68%0.25%$9.15 - $11.99 $ 12.9920%59157107
Vanguard Health Care Fund 2013-09-30 Reduce -15.74%0.24%$9.15 - $11.99 $ 12.9920%38240700
Charles Brandes 2013-09-30 Sold Out 0.07%$9.15 - $11.99 $ 12.9920%0
Joel Greenblatt 2013-09-30 Reduce -69.22%0.02%$9.15 - $11.99 $ 12.9920%18744
Charles Brandes 2013-06-30 Reduce -96.31%1.54%$7.09 - $9.64 $ 12.9953%624088
Dodge & Cox 2013-06-30 Reduce -14.79%0.14%$7.09 - $9.64 $ 12.9953%81801130
Joel Greenblatt 2013-06-30 Reduce -51.28%0.03%$7.09 - $9.64 $ 12.9953%60894
Leon Cooperman 2013-03-31 Add 13.43%0.24%$5.73 - $7.81 $ 12.9982%16473300
Joel Greenblatt 2013-03-31 Reduce -20.11%0.01%$5.73 - $7.81 $ 12.9982%124980
Ray Dalio 2013-03-31 Sold Out 0.0025%$5.73 - $7.81 $ 12.9982%0
Michael Price 2012-12-31 Add 13.33%0.16%$5.07 - $5.82 $ 12.99137%1700000
Mario Gabelli 2012-12-31 Add 20.63%0.02%$5.07 - $5.82 $ 12.99137%2418305
Ray Dalio 2012-12-31 Reduce -22.61%$5.07 - $5.82 $ 12.99137%42784
Michael Price 2012-09-30 Add 149.46%0.78%$4.99 - $5.82 $ 12.99135%1500000
Leon Cooperman 2012-09-30 Add 24.03%0.31%$4.99 - $5.82 $ 12.99135%14331900
Joel Greenblatt 2012-09-30 Add 23.88%0.01%$4.99 - $5.82 $ 12.99135%135038
Leon Cooperman 2012-06-30 Reduce -32.67%0.65%$5.51 - $6.25 $ 12.99120%11554900
Michael Price 2012-06-30 Add 140.52%0.29%$5.51 - $6.25 $ 12.99120%601300
Joel Greenblatt 2012-06-30 Add 971.66%0.04%$5.51 - $6.25 $ 12.99120%109009
Ray Dalio 2012-06-30 New Buy$5.51 - $6.25 $ 12.99120%48184
David Tepper 2012-03-31 Sold Out 5.4%$5.3 - $6.36 $ 12.99138%0
Vanguard Health Care Fund 2012-03-31 Add 28.93%0.29%$5.3 - $6.36 $ 12.99138%46800000
Michael Price 2012-03-31 New Buy0.21%$5.3 - $6.36 $ 12.99138%250000
Ray Dalio 2012-03-31 Sold Out 0.18%$5.3 - $6.36 $ 12.99138%0
Joel Greenblatt 2012-03-31 New Buy0.01%$5.3 - $6.36 $ 12.99138%10172
David Tepper 2011-12-31 New Buy5.4%$5.09 - $5.9 $ 12.99135%7797503
Vanguard Health Care Fund 2011-12-31 Add 37.5%0.27%$5.09 - $5.9 $ 12.99135%36300000
Ray Dalio 2011-12-31 Add 224.01%0.12%$5.09 - $5.9 $ 12.99135%1956684
Leon Cooperman 2011-09-30 Add 86.1%1.36%$5.62 - $7.28 $ 12.9997%16725200
Ray Dalio 2011-09-30 Add 361.7%0.04%$5.62 - $7.28 $ 12.9998%603900
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Boston Scientific Inc

Diamond Hill Capital Comments on Boston Scientific Corp - Oct 17, 2014

Shares of Boston Scientific Corp. (BSX) declined as investors focused on potential liabilities stemming from legal disputes. We continue to see improvement in revenue trends and believe they will be key factors in closing the discount to our estimate of intrinsic value over time.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Boston Scientific Corp - Jul 25, 2014

•Medical device manufacturer Boston Scientific Corp. (BSX) reported solid earnings for the first quarter but investors focused on near-term headwinds in the cardiac-rhythm management business. The company also announced a delay in potential approval for its Watchman’s heart device. Given the breadth of the company’s pipeline, potential for margin upside, and attractive valuation, we continue to like the outlook for the shares going forward.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Boston Scientific Corp - Jun 26, 2014

Medical device manufacturer Boston Scientific Corp. (BSX) benefitted from continued revenue acceleration and the launch of a new high margin stent with the potential for sizeable share gains.



From Diamond Hill Capital's Select Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Boston Scientific Corp - Jan 15, 2014

Boston Scientific Corp. (BSX), a medical device manufacturer, recently reported its first quarter of growth in more than three years, while also raising its earnings outlook. An emerging pipeline of new products offers the potential for continued improvement and the potential to return to mid-single digit revenue growth.

From Diamond Hill Capital (Trades, Portfolio) Large Cap Fund third quarter 2013 commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Boston Scientific Inc

Diamond Hill Capital Comments on Boston Scientific Corp
Shares of Boston Scientific Corp. (BSX) declined as investors focused on potential liabilities stemming from legal disputes. We continue to see improvement in revenue trends and believe they will be key factors in closing the discount to our estimate of intrinsic value over time. Read more...
Diamond Hill Capital Comments on Boston Scientific Corp
•Medical device manufacturer Boston Scientific Corp. (BSX) reported solid earnings for the first quarter but investors focused on near-term headwinds in the cardiac-rhythm management business. The company also announced a delay in potential approval for its Watchman’s heart device. Given the breadth of the company’s pipeline, potential for margin upside, and attractive valuation, we continue to like the outlook for the shares going forward. Read more...
Diamond Hill Capital Comments on Boston Scientific Corp
Medical device manufacturer Boston Scientific Corp. (BSX) benefitted from continued revenue acceleration and the launch of a new high margin stent with the potential for sizeable share gains. Read more...
Diamond Hill Capital Comments on Boston Scientific Corp
Boston Scientific Corp. (BSX), a medical device manufacturer, recently reported its first quarter of growth in more than three years, while also raising its earnings outlook. An emerging pipeline of new products offers the potential for continued improvement and the potential to return to mid-single digit revenue growth. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 46.30
BSX's P/E(ttm) is ranked higher than
72% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 52.10 vs. BSX: 46.30 )
BSX' s 10-Year P/E(ttm) Range
Min: 14.05   Max: 89.4
Current: 46.3

14.05
89.4
P/B 2.60
BSX's P/B is ranked higher than
69% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.30 vs. BSX: 2.60 )
BSX' s 10-Year P/B Range
Min: 0.59   Max: 12.21
Current: 2.6

0.59
12.21
P/S 2.40
BSX's P/S is ranked higher than
67% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. BSX: 2.40 )
BSX' s 10-Year P/S Range
Min: 1.02   Max: 10.34
Current: 2.4

1.02
10.34
PFCF 24.50
BSX's PFCF is ranked higher than
87% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. BSX: 24.50 )
BSX' s 10-Year PFCF Range
Min: 7.25   Max: 192.5
Current: 24.5

7.25
192.5
EV-to-EBIT 59.31
BSX's EV-to-EBIT is ranked higher than
71% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 35.63 vs. BSX: 59.31 )
BSX' s 10-Year EV-to-EBIT Range
Min: 11.1   Max: 184.9
Current: 59.31

11.1
184.9
Current Ratio 1.81
BSX's Current Ratio is ranked higher than
59% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. BSX: 1.81 )
BSX' s 10-Year Current Ratio Range
Min: 0.52   Max: 3.57
Current: 1.81

0.52
3.57
Quick Ratio 1.28
BSX's Quick Ratio is ranked higher than
59% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. BSX: 1.28 )
BSX' s 10-Year Quick Ratio Range
Min: 0.33   Max: 2.82
Current: 1.28

0.33
2.82

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.53
BSX's Price/DCF (Projected) is ranked higher than
87% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 28.60 vs. BSX: 1.53 )
BSX' s 10-Year Price/DCF (Projected) Range
Min: 0.5   Max: 5.76
Current: 1.53

0.5
5.76
Price/Median PS Value 1.09
BSX's Price/Median PS Value is ranked higher than
66% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. BSX: 1.09 )
BSX' s 10-Year Price/Median PS Value Range
Min: 0.48   Max: 4.3
Current: 1.09

0.48
4.3
Earnings Yield (Greenblatt) 1.70
BSX's Earnings Yield (Greenblatt) is ranked higher than
52% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. BSX: 1.70 )
BSX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 9
Current: 1.7

0.5
9
Forward Rate of Return (Yacktman) 2.81
BSX's Forward Rate of Return (Yacktman) is ranked higher than
81% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 1.45 vs. BSX: 2.81 )
BSX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3   Max: 46
Current: 2.81

3
46

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:BSX.Germany
Boston Scientific, Inc., is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's products were offered for sale by seven core businesses - Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Women's Health, Neuromodulation, and Electrophysiology. The Company derives 33 percent of its sales from its Interventional Cardiology business, 27 percent of its sales from its CRM business, 16 percent of its sales from its Endoscopy business, 10 percent of its sales from its Peripheral Interventions business, six percent of its sales from its Urology/Women's Health business, four percent of its sales from its Neuromodulation business, and two percent of its sales from its Electrophysiology business. It develops, manufactures and markets a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including: Implantable cardiac defibrillator systems used to detect and treat abnormally fast heart rhythms that could result in sudden cardiac death, including implantable cardiac resynchronization therapy defibrillator systems used to treat heart failure; and Implantable pacemaker systems used to manage slow or irregular heart rhythms, including implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure. Within the Company's Electrophysiology business, it offers medical devices for the diagnosis and treatment of cardiac arrhythmias. Included in its product offerings are RF generators, intracardiac ultrasound and steerable ablation catheters, and diagnostic catheters. The Company's main competitors include Abbott Laboratories; Medtronic, Inc.; St. Jude Medical, Inc.; and Johnson & Johnson as well as a wide range of medical device companies that sell a single or limited number of competitive products or participate in only a specific market segment. It also faces competition from non-medical device companies, such as pharmaceutical companies, which may offer alternative therapies for disease states intended to be treated using its products. The medical devices that the Company manufactures and markets are subject to regulation by numerous regulatory bodies, including the FDA and comparable international regulatory agencies.
» More Articles for BSX

Headlines

Articles On GuruFocus.com
Diamond Hill Capital Comments on Boston Scientific Corp Oct 17 2014 
Diamond Hill Capital Comments on Boston Scientific Corp Jul 25 2014 
Diamond Hill Capital Comments on Boston Scientific Corp Jun 26 2014 
Diamond Hill Select Fund Commentary – First Quarter 2014 Jun 25 2014 
Diamond Hill Capital Comments on Boston Scientific Corp Jan 15 2014 
Vanguard Health Care Fund Selling Update Oct 30 2013 
Diamond Hill Funds Q3 Market Review and Large-Cap Fund Commentary Oct 29 2013 
Weekly CFO Sells Highlight: BSX, RKUS, MCRL, LRAD and SWKS Sep 08 2013 
Charles Brandes Top Second Quarter Portfolio Changes Aug 09 2013 
comment on BSX May 22 2013 


More From Other Websites
Street Talk: BABA is back Oct 23 2014
One Reason Boston Scientific (BSX) Stock Is Climbing Today Oct 23 2014
Boston Scientific attracts the bulls Oct 23 2014
Boston Scientific Turnaround Complete, CEO Mahoney Says Oct 22 2014
Boston Scientific Earnings, Revenues in Line; View Up Oct 22 2014
After Multiyear Turnaround, Is Boston Scientific Finally (and Really) Back? Oct 22 2014
Boston Scientific (BSX) Earnings Report: Q3 2014 Conference Call Transcript Oct 22 2014
Why Boston Scientific (BSX) Stock Is Up Today Oct 22 2014
Morgan Stanley Reviews Boston Scientific Q3 Results Oct 22 2014
[$$] Boston Scientific Swings to Profit on Higher Sales Oct 22 2014
Boston Scientific 3rd-qtr profit up on heart device sales Oct 22 2014
Boston Scientific Corp Earnings Call scheduled for 8:00 am ET today Oct 22 2014
Abbott’s Profit Rises as Nutrition Products Grow Oct 22 2014
Boston Scientific profit up on heart device sales Oct 22 2014
Boston Scientific meets 3Q profit forecasts Oct 22 2014
Boston Scientific meets 3Q profit forecasts Oct 22 2014
7:09 am Boston Scientific reports EPS in-line, beats on revs; guides Q4 EPS in-line, revs in-line;... Oct 22 2014
Q3 2014 Boston Scientific Corp Earnings Release - Before Market Open Oct 22 2014
BOSTON SCIENTIFIC CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Oct 22 2014
Boston Scientific Announces Results For Third Quarter Ended September 30, 2014 Oct 22 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK